At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Trading 08-26 11:30:42 EDT
212.23
+0.85
+0.40%
High216.50Low198.94Vol998.03K
Open209.32D1 Closing211.38Amplitude8.31%
Mkt Cap45.49BTradable Cap39.05BTotal Shares214.34M
T/O207.87MT/O Rate0.54%Tradable Shares184.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million
Reuters  ·  18:52
Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
Dow Jones  ·  13 minutes ago
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
Movement Alert｜Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13
Market Focus  ·  45 minutes ago
Movement Alert｜Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13
US FDA Approves Revolution Medicines' Pancreatic Cancer Drug
Reuters  ·  48 minutes ago
US FDA Approves Revolution Medicines' Pancreatic Cancer Drug
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  53 minutes ago
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151
THOMSON REUTERS  ·  08-21
Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151
Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD
TIPRANKS  ·  08-21
Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD
Movement Alert｜Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum
Market Focus  ·  08-18
Movement Alert｜Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum
Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal
Reuters  ·  08-13
Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
GlobeNewswire  ·  08-12
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities
Dow Jones  ·  08-12
Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities
U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,
Reuters  ·  08-11
U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,
Tango Falls After Wider-than-Expected Quarterly Loss
Reuters  ·  08-11
Tango Falls After Wider-than-Expected Quarterly Loss
U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health
Reuters  ·  08-11
U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health
Truist Raises Revolution Medicines PT on Lung Cancer Pipeline Potential
Reuters  ·  08-11
Truist Raises Revolution Medicines PT on Lung Cancer Pipeline Potential
BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development
Stock News  ·  08-11
BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development
Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
TIPRANKS  ·  08-10
Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
BeOne Medicines partners with Revolution Medicines for clinical development
TIPRANKS  ·  08-10
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines Teams with Revolution Medicines on RAS Cancer Drug Development, Asia Rights Deal
Reuters  ·  08-10
BeOne Medicines Teams with Revolution Medicines on RAS Cancer Drug Development, Asia Rights Deal
Beone Medicines - Receives Exclusive Rights to Four Revolution Medicines Assets in Select Asian Markets
THOMSON REUTERS  ·  08-10
Beone Medicines - Receives Exclusive Rights to Four Revolution Medicines Assets in Select Asian Markets

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--